Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis
NCT: NCT07266688 · COMPLETED
Brief Summary
This study aims to evaluate the effectiveness and safety of Bactorinol® nasal spray, a medical device containing winterized Pistacia lentiscus oil, in adults with vasomotor rhinitis. Vasomotor rhinitis is a chronic condition characterized by nasal congestion, rhinorrhea, and impaired nasal airflow. In this multicenter, prospective, randomized, controlled clinical trial, 100 adult participants will be assigned in a 1:1 ratio to receive either Bactorinol® nasal spray or isotonic saline solution for 20 consecutive days. The primary objective is to determine whether Bactorinol® improves nasal airflow, measured by Peak Nasal Inspiratory Flow (PNIF). Secondary objectives include evaluating changes in symptoms and quality of life using the SNOT-22 questionnaire, assessing nasal cytology, and monitoring treatment compliance and adverse events. The results of this study may help identify a non-pharmacological, natural-extract-based treatment option for patients with vasomotor rhinitis.
Frequently Asked Questions
What is Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis?
Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis is a clinical trial registered under NCT07266688. Current status: COMPLETED.
What is the status of NCT07266688?
The current status of NCT07266688 (Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis) is: COMPLETED.
When did Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis start?
Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis started on 2025-12-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.